Esaote foresees new applications for Artoscan
This article was originally published in Clinica
Esaote Biomedica is evaluating the clinical potential of its Artoscan limb and joint MRI system in diagnosing breast lesions. The Italian company also revealed, in the prospectus it issued for its recent heavily oversubscribed share offering, that it is investigating the product's suitability for shoulder examinations. Esaote had sold over 140 Artoscans by December 1995, 70% in international markets.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.